Association of HLA class II genes with clinical hyporesponsiveness to trivalent inactivated influenza vaccine in children

Vaccine

Volumn 31, Issue 7, 2013, Pages 1123-1128

  Narwaney, Komal J ^a,b   Glanz, Jason M ^a,b   Norris, Jill M ^a   Fingerlin, Tasha E ^a   Hokanson, John E ^a   Rewers, Marian ^c,d   Hambidge, Simon J ^a,b,c,e  

^a Global Health and Health Disparities   (United States)

^b Kaiser Permanente Colorado   (United States)

^c Children's Hospital Colorado   (United States)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e DENVER HEALTH   (United States)

Author keywords

Clinical hyporesponsiveness; HLA; Influenza vaccine

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR4 ANTIGEN; HLA DR7 ANTIGEN; HLA DRB1 ANTIGEN; INFLUENZA VACCINE;

ARTICLE; CAUCASIAN; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HISPANIC; HUMAN; INFANT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEASONAL INFLUENZA; TREATMENT RESPONSE;

CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLORADO; FEMALE; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; RETROSPECTIVE STUDIES; VACCINES, INACTIVATED;

EID: 84872595505     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.026     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention - Influenza; 2012 [18.02.2].
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
3. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010, 59:1057-1062.
4. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
5. O'Brien M.A., Uyeki T.M., Shay D.K., Thompson W.W., Kleinman K., McAdam A., et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004, 113:585-593.
6. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
7. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-62.
8. Lambkin R., Novelli P., Oxford J., Gelder C. Human genetics and responses to influenza vaccination: clinical implications. Am J Pharmacogenomics 2004, 4:293-298.
9. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
10. Beran J., Vesikari T., Wertzova V., Karvonen A., Honegr K., Lindblad N., et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009, 200:1861-1869.
11. Jackson L.A., Gaglani M.J., Keyserling H.L., Balser J., Bouveret N., Fries L., et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010, 10:71.
12. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
13. Wang C., Tang J., Song W., Lobashevsky E., Wilson C.M., Kaslow R.A. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004, 39:978-988.
14. Li Y., Ni R., Song W., Shao W., Shrestha S., Ahmad S., et al. Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet 2009, 126:685-696.
15. Milich D.R., Leroux-Roels G.G. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003, 2:248-257.
16. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001, 20:430-438.
17. Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., Poland G.A. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006, 193:655-663.
18. Gelder C.M., Lambkin R., Hart K.W., Fleming D., Williams O.M., Bunce M., et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002, 185:114-117.
19. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008, 26(Suppl. 4):D35-D40.
20. Kimman T.G., Vandebriel R.J., Hoebee B. Genetic variation in the response to vaccination. Community Genet 2007, 10:201-217.
21. Rewers M., Bugawan T.L., Norris J.M., Blair A., Beaty B., Hoffman M., et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 1996, 39:807-812.
22. Ritzwoller D.P., Bridges C.B., Shetterly S., Yamasaki K., Kolczak M., France E.K. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005, 116:153-159.
23. Call S.A., Vollenweider M.A., Hornung C.A., Simel D.L., McKinney W.P. Does this patient have influenza. JAMA 2005, 293:987-997.
24. Marsden-Haug N., Foster V.B., Gould P.L., Elbert E., Wang H., Pavlin J.A. Code-based syndromic surveillance for influenzalike illness by International Classification of Diseases, Ninth Revision. Emerg Infect Dis 2007, 13:207-216.
25. Centers for Disease Control and Prevention - 2007-2008 Influenza Season - Questions and Answers; 2012 [18.02.12].
26. Colorado Department of Public Health and Environment - Disease Control and Environmental Epidemiology Division - Influenza Surveillance; 2012 [18.02.12].
27. Fiore A.E., Shay D.K., Haber P., Iskander J.K., Uyeki T.M., Mootre G., et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-60.
28. Emery L.M., Babu S., Bugawan T.L., Norris J.M., Erlich H.A., Eisenbarth G.S., et al. Newborn HLA-DR,DQ genotype screening: age- and ethnicity-specific type 1 diabetes risk estimates. Pediatr Diabetes 2005, 6:136-144.
29. Glanz J.M., Newcomer S.R., Hambidge S.J., Daley M.F., Narwaney K.J., Xu S., et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med 2011, 165:749-755.
30. Hsu L.C., Lin S.R., Hsu H.M., Chao W.H., Hsieh J.T., Wang M.C., et al. Ethnic differences in immune responses to hepatitis B vaccine. Am J Epidemiol 1996, 143:718-724.
31. Rager-Zisman B., Bazarsky E., Skibin A., Tam G., Chamney S., Belmaker I., et al. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol 2004, 11:913-918.
32. Poland G.A., Jacobson R.M., Colbourne S.A., Thampy A.M., Lipsky J.J., Wollan P.C., et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999, 17:1525-1531.
33. Caillat-Zucman S., Gimenez J.J., Wambergue F., Albouze G., Lebkiri B., Naret C., et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998, 53:1626-1630.
34. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., Poland G.A. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis 2005, 191:515-519.
35. Petrie J.G., Ohmit S.E., Johnson E., Cross R.T., Monto A.S. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203:1309-1315.
36. France E.K., Smith-Ray R., McClure D., Hambidge S., Xu S., Yamasaki K., et al. Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants. Arch Pediatr Adolesc Med 2006, 160:1277-1283.
37. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342:232-239.
38. Keren R., Wheeler A., Coffin S.E., Zaoutis T., Hodinka R., Heydon K. ICD-9 codes for identifying influenza hospitalizations in children. Emerg Infect Dis 2006, 12:1603-1604.